LASA vs THEMISMED: Stock Comparison

Lasa Supergenerics Limited vs Themis Medicare Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Themis Medicare Limited is the larger company by market capitalisation. Lasa Supergenerics Limited shows lower leverage, while Themis Medicare Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Lasa Supergenerics Limited and Themis Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LASA is more favourable on 1 of 11 scored metrics and THEMISMED on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
THEMISMED is the larger company
₹972 Cr vs ₹35 Cr
EPS
THEMISMED has higher earnings per share
₹0.12 vs ₹-6.8
Dividend Yield
THEMISMED has a higher dividend yield
0.43% vs 0%
Revenue Growth (TTM YoY)
THEMISMED has faster revenue growth
6.7% vs 0%
Qtr Sales Growth
THEMISMED has stronger quarterly sales growth
6.74% vs -100%
Qtr Profit Growth
THEMISMED has stronger quarterly profit growth
192% vs -139%
ROE
THEMISMED has a higher ROE
0.29% vs -19.6%
ROCE
THEMISMED has a higher ROCE
2.74% vs -18.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLASATHEMISMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLASATHEMISMED
Live Price₹6.86₹105.78
Day Change0.59%-1.99%
Volume9,68534,271
52-Week High₹14.08₹148
52-Week Low₹5.67₹64.95
Distance from 52W High-51.28%-28.53%

Valuation

MetricLASATHEMISMED
Market Cap₹35 Cr₹972 Cr
P/E Ratio883.33x
P/B Ratio2.45x
EPS₹-6.8₹0.12
Book Value₹9.89₹43.06
Dividend Yield0%0.43%

Growth

MetricLASATHEMISMED
Revenue Growth (TTM YoY)0%6.7%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-100%6.74%
Qtr Profit Growth-139%192%

Profitability & Leverage

MetricLASATHEMISMED
ROE-19.6%0.29%
ROCE-18.2%2.74%
Net Margin-135.6%0.33%
Operating Margin-29.3%-2.9%
Debt to Equity0.2x25.11x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricLASATHEMISMED
Promoter Holding53.65%57.5%
FII Holding0%0.01% 0.1 pp
DII Holding0%0.01%
Public Holding46.35%32.87% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Lasa Supergenerics Limited and Themis Medicare Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.